QIAGEN announced a new commercial partnership and co-marketing agreement with ID Solutions on May 22, 2025. ID Solutions is a French provider of high-quality digital PCR (dPCR) assays for oncology and other disease areas.
This collaboration aims to expand the availability of dPCR assays for oncology research applications, leveraging QIAGEN’s global reach and automation expertise with ID Solutions’ assay development and manufacturing capabilities. ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN’s QIAcuity platforms.
QIAGEN will commercialize these kits, initially in Europe, with potential for future expansion into other regions. This agreement supports QIAGEN’s strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research, complementing its existing PanCancer Kits and LNA Mutation Assays.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.